Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
=================================================================================================================================================================================

* Robert H. I. Andtbacka
* Frances Collichio
* Kevin J. Harrington
* Mark R. Middleton
* Gerald Downey
* Katarina Ӧhrling
* Howard L. Kaufman